Kuti Baruch

Kuti Baruch is a prominent biopharmaceutical expert with significant experience in research and development, currently serving as Vice President of R&D at ImmunoBrain Checkpoint since November 2016. This company specializes in innovative immunotherapies for neurological disorders, with a focus on Alzheimer's disease and the PD-1/PD-L1 immune checkpoint pathway. Prior to this role, Kuti Baruch led R&D at the Weizmann Institute of Science from 2009 to October 2016, engaging in basic and translational research on immune checkpoint blockade for Alzheimer's. Kuti Baruch holds a Ph.D. in Neuroimmunology from the Weizmann Institute, as well as M.Sc. and B.Sc. degrees in Molecular Genetics and Biology, respectively, from Tel Aviv University.